1. Identification of heterogenous treatment response trajectories to anti-IL6 receptor treatment in rheumatoid arthritis
- Author
-
Cecilie L. Bager, M. H. Tang, Anne-Christine Bay-Jensen, Søren Brunak, P. Frederiksen, Morten A. Karsdal, and Joseph P.M. Blair
- Subjects
Male ,0301 basic medicine ,Oncology ,lcsh:Medicine ,Disease ,Severity of Illness Index ,Biomarkers, Pharmacological ,Arthritis, Rheumatoid ,chemistry.chemical_compound ,0302 clinical medicine ,Receptor ,skin and connective tissue diseases ,lcsh:Science ,Multidisciplinary ,Remission Induction ,Middle Aged ,METHOTREXATE ,Treatment Outcome ,Antirheumatic Agents ,Rheumatoid arthritis ,Disease Progression ,Biomarker (medicine) ,Drug Therapy, Combination ,Female ,medicine.symptom ,BONE ,medicine.drug ,Adult ,musculoskeletal diseases ,medicine.medical_specialty ,BIOMARKERS ,Inflammation ,Blood Sedimentation ,Antibodies, Monoclonal, Humanized ,Article ,03 medical and health sciences ,Tocilizumab ,CARTILAGE ,Internal medicine ,Machine learning ,medicine ,Humans ,TOCILIZUMAB ,Aged ,business.industry ,lcsh:R ,medicine.disease ,Receptors, Interleukin-6 ,Methotrexate ,030104 developmental biology ,chemistry ,Etiology ,lcsh:Q ,business ,030217 neurology & neurosurgery - Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease with fluctuating course of progression. Despite substantial improvement in treatments in recent years, treatment response is still not guaranteed. The aim of this study was to identify variation in Disease Activity Score 28 (DAS28) of RA patients in response to Tocilizumab, and to investigate both molecular and clinical factors influencing response. Clinical and biochemical data for 485 RA patients receiving Tocilizumab in combination with methotrexate were extracted from the LITHE phase III clinical study (NCT00106535), and post-hoc analysis conducted. Latent class mixed models were used to identify statistically distinct trajectories of DAS28 after the initiation of treatment. Biomarker measurements were then analysed cross-sectionally and temporally, to characterise patients by serological biomarkers and clinical factors. We identified three distinct trajectories of drug response: class 1 (n = 85, 17.5%), class 2 (n = 338, 69.7%) and class 3 (n = 62, 12.8%). All groups started with high DAS28 on average (DAS28 > 5.1). Class 1 showed the least reduction in DAS28, with significantly more patients seeking escape therapy (p p
- Published
- 2020
- Full Text
- View/download PDF